entertainment -WSS

entertainment

author：explore 2025-09-30 19:27:04 - browse：2487

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： How to use technology to prevent future drug shortages

hotspot

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

The future of health care in the House

What to expect at HLTH 2023, the health care industry conference

Bill would stop addiction treatment from triggering child abuse inquiry

Stroke deaths set to near 10 million globally by 2050

Man killed during FBI raid in connection with threats against Biden, other officials

hotspot

entertainment

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Sana to lay off nearly a third of staff, de

Tori Bowie and the unacceptable rates of Black maternal death

Friends ask where James Watson's attitudes about race came from

Guidelines to prevent youth baseball injuries need more muscle

Chemotherapy drug shortage eases slightly but still widespread

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Colorectal cancer study finds potential in overlooked immune cell

Drug repurposing or repositioning? The language matters

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

hotspot

Anavex keeps shifting the goalposts in its clinical trials

AI can decode, harness the power of the humane immune system

The future of health care in the House

The future of health care in the House

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

focus

focus

hotspot

explore